About Genentech
Genentech is a company based in San Francisco (United States) founded in 1976 was acquired by Roche in March 2009. Genentech has completed 5 acquisitions, including Jecure Therapeutics, MyVisionTrack and RQX Pharmaceuticals. Genentech offers products and services including Medicines and Clinical Trials. Genentech operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Latest Funding Round$404.2K (USD), Grant
Sep 2023
- InvestorsRoche
& 1 more
- Investments & AcquisitionsJecure Therapeutics
& 4 more
- Acquired byRoche
(Mar 2009)
Products & Services of Genentech
Genentech offers a comprehensive portfolio of products and services, including Medicines and Clinical Trials.
Treatments for oncology and other diseases
Conducts studies for new therapies and patient support
Funding Insights of Genentech
- Total Rounds 1
- Last Round Grant — $404,201
- First Round $404,201
(Sep 2023)
- Investors Count 1
All 1 funding rounds of Genentech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $404,201 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Genentech
Genentech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Roche and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Genentech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genentech
774 people are tracked at Genentech (335 in leadership, 5 in board & advisors, 434 in team).
| Name | Role | Group |
|---|---|---|
Stephanie Wang | Director/us Commercial Lead, New Product Commercialization - Oncology And Immunology Pipeline | Leadership |
Natalia Callaway | Senior Medical Director, Product Development/early Research And Development Ophthalmology | Leadership |
Aaron Chan | Director | Leadership |
Qianru Li | Executive Director And Senior Associate General Counsel, Therapeutics IP Lead | Leadership |
Raymond Meng | Medical Director, Early Clinical Development | Leadership |
William Berglind | Senior Group Director | Leadership |
mike lanning | Senior Director Employer Account Executives | Leadership |
Michelle Byrtek | Senior Director, People And Product Leader, Data And Statistical Sciences | Leadership |
Maura Dickler | Vice President, Global Product Development Oncology, Breast And Gynecologic Cancers | Leadership |
Christian Luque | Regulatory Program Director | Leadership |
Ben Schwartz | Director, US Pipeline, Cardiovascular, Renal, Metabolism | Leadership |
Elena Bernedo Arzac | Senior Vice President, Global Product Strategy, Oncology | Leadership |
Michelle Santy | Program Director | Leadership |
Jesse Woodhull | Director Information Technology And Operational Technology (itot) | Leadership |
Lauren Cupps | Solid Tumor Marketing Team Director | Leadership |
Scott Kohler | Senior Director, Corporate Groups & Employee Relations | Leadership |
Natalie Abts | Head Of Human Factors Engineering - Device And Packaging Development Leadership | Leadership |
Rob Schilling | Clinical Program Director | Leadership |
Lauren Bush | Gcs Infrastructure & Architecture Director | Leadership |
Giulio Barteselli | Group Medical Director, Ophthalmology Product Development | Leadership |
754 more people are available in the full profile.
Complete people profiles for Genentech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genentech
Genentech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Jecure Therapeutics, MyVisionTrack and RQX Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vision test for self monitoring of vision at home | myvisiontrack.com | Richardson, United States | 2006 | Sep 2019 | •••• | |
Therapeutics for NASH and liver fibrosis are discovered and developed. | jecuretx.com | San Diego, United States | 2015 | Nov 2018 | •••• | |
Selective estrogen receptor degraders are developed for breast cancer treatment. | seragonpharm.com | San Diego, United States | 2013 | Jul 2014 | •••• | |
Novel antibiotics for community and hospital infections are developed. | rqxpharmaceuticals.com | San Diego, United States | 2010 | Feb 2013 | •••• | |
Drugs for immune system diseases are developed and tested. | tanox.com | Houston, United States | 1986 | Nov 2006 | $919M |
Complete acquisition details for Genentech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genentech
8 dated milestones of Genentech across 47 years, from founding to its latest funding, stage changes and deals.
- Founded Genentech is founded.
- Acquisition Acquires Tanox.
- Exit Acquired by Roche.
- Acquisition Acquires RQX Pharmaceuticals.
- Acquisition Acquires Seragon Pharmaceuticals.
- Acquisition Acquires Jecure Therapeutics.
- Acquisition Acquires MyVisionTrack.
- Funding First funding round of $404K.
Competitors of Genentech
Genentech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Genentech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genentech
The website of Genentech (gene.com) receives about 492.6K visits a month and ranks #97,838 among all websites worldwide, #6,252 in Science and Education.
- Monthly visits492.6K
▲ 23.7% vs previous month
- Unique visitors180.8K
per month
- Global rank#97,838
among all websites
- Category rank#6,252
Science and Education · Science and Education
- Bounce rate40%
- Pages per visit4.4
- Average visit3 min 10 sec
- DevicesDesktop 62% · Mobile 38%
Websites whose visitors overlap most with Genentech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
science.org | science.org | 100% | – | #9,517 | – |
| researchgate.net | 99% | 101.7M | #345 | View details | |
| orcid.org | 94% | 11.6M | #5,168 | View details | |
| mdpi.com | 91% | 23.6M | #2,770 | View details | |
pnas.org | pnas.org | 88% | – | #23,651 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Genentech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Genentech
Complete news archive for Genentech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Genentech
10 companies that operate in the same segment as Genentech (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genentech
Genentech was founded in 1976 and raised its 1st funding round 47 years after it was founded.
Genentech is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Genentech was founded in 1976 in San Francisco, United States, as a biotechnology firm. Research and development efforts are directed toward manufacturing pharmaceutical products across multiple therapeutic areas, including oncology, immunology, neurology, metabolism, infectious diseases, and ophthalmology. Clinical trial information services are also offered to support medical research and development activities in the sector.
Genentech's top competitors include Merck, Roivant Sciences and AbbVie.
Genentech offers Medicines and Clinical Trials.
Genentech has made 5 acquisitions, including Jecure Therapeutics, MyVisionTrack, and RQX Pharmaceuticals.
Genentech operates through Genentech, Inc..
Yes. Genentech was acquired by Roche in March 2009.
The website of Genentech receives about 493 thousand visits a month and ranks #97,838 among all websites worldwide.